QuickLinks -- Click here to rapidly navigate through this document
U.S. Patents Owned or Licensed by MedImmune, Inc.*
Product/ Project | US Patent No. | Subject Matter | Expiration Date | |||
---|---|---|---|---|---|---|
E. coli | 4,795,803 | Adhesin antigens | 1/3/2006 | |||
5,804,198 | Adhesin vaccines | 9/8/2015 | ||||
6,291,649 | Anti-adhesin antibodies | 3/2/2005 | ||||
6,500,434 | Chaperone and Adhesin Proteins: Vaccines, Diagnostic and Methods for Treating Infections | 4/23/2019 | ||||
Vitaxin | 5,753,230 | Use of antibodies anti-avb3 antibodies to inhibit angiogenesis in tumors and inflamed tissue | 5/19/2015 | |||
MEDI-507 | 5,730,979 | Anti-CD2 antibodies and their use in treating T-cell mediated immune responses | 3/24/2015 | |||
5,951,983 | Anti-CD2 antibodies and their use in treating T-cell mediated immune responses | 9/14/2016 | ||||
5,817,311 | Use of anti-CD2 antibodies in treating T-cell mediated immune responses | 10/6/2015 | ||||
HPV | 6,228,368 | Capsomeres containing HPV L1 protein and their use in preventing and treating HPV infection | 10/6/2017 | |||
6,066,324 | HPV VLPs containing L1 protein with deletions | 10/9/2015 | ||||
6,261,765 | Disassembly/reassembly of Papillomavirus Virus Like Particles | 9/5/2017 | ||||
6,165,471 | HPV capsomeres with reduced assembly capacity | 7/2/2018 | ||||
6,153,201 | Oral Immunization with Papillomavirus Virus Like Particles | 3/9/2013 | ||||
6,361,778 | Papillomavirus Like Particles, Fusion Proteins as well as Processes for Their Production | 9/16/2019 | ||||
6,416,945 | Disassembly/reassembly of Papillomavirus Virus Like Particles | 9/5/2017 | ||||
RSV | 5,824,307 | Synagis® & other anti-RSV antibodies and their use in treating or preventing RSV infection | 10/20/2015 | |||
5,582,827 | Immunoglobulin from plasma for treatment of RSV | 12/10/2013 | ||||
4,800,078 | Treatment of respiratory disease caused by RSV using human gamma globulin | 1/24/2006 | ||||
5,412,077 | Effective Antibody Titers Against Respiratory Viruses | 8/4/2020 | ||||
Strep | 5,928,900 | Pad1 protein | 7/27/2016 | |||
5,981,229 | DNA encoding Exp1 and PlpA proteins | 11/9/2016 | ||||
5,834,278 | DNA encoding pneumococcal MsrA | 5/1/2016 | ||||
6,245,335 | Streptococcal choline binding proteins | 5/1/2017 | ||||
5,736,367 | Vectors and Prokaryotes which Autocatalytically Delete Resistance | 4/7/2018 | ||||
5,798,243 | Bacterial Peptide Methionine Sulfoxide Reductase an Adhesion Associated Protein, and Antibiotic Therapies | 5/1/2016 | ||||
6,420,135 | Streptococcus pneumoniae polynucleotides and sequences | 10/03/17 | ||||
6,503,511 | Derivatives of Choline Binding Proteins for Vaccines | 4/6/2019 | ||||
IL-9 | 5,157,112 | Antibodies which specifically bind mammalian T cell growth factor P40 | 10/20/2009 | |||
6,037,149 | DNA and RNA molecules that encode Met-IL-9 and their use for recombinant production | 8/23/2016 | ||||
5,580,753 | DNA molecules encoding IL-9 and their use for recombinant production | 12/3/2013 | ||||
5,734,037 | Nucleic acid molecules that hybridize to DNA encoding IL-9 | 5/23/2009 | ||||
5,414,071 | Human IL-9 protein | 5/9/2012 | ||||
5,164,317 | Method for enhancing proliferation of mast cells using IL-9 | 3/23/2010 | ||||
5,132,109 | Method for enhancing IgG production using IL-9 and IL-4 | 10/5/2010 | ||||
5,246,701 | Method to inhibit IgE production using anti-IL-9 antibodies or other IL-9 inhibitors | 10/5/2010 |
5,962,269 | Processes and hybridomas for producing anti-IL-9 receptor antibodies | 10/5/2016 | ||||
6,261,559 | Treating asthmatic symptoms using anti-IL-9 antibodies | 8/23/2016 | ||||
5,789,237 | Nucleic acid molecules that hybridize to DNAs encoding human and murine IL-9 receptors | 8/4/2015 | ||||
5,750,377 | Methods for production of mammalian T cell growth factor P40 | 5/12/2015 | ||||
5,116,951 | IL-9 receptor protein | 9/19/2010 | ||||
5,587,302 | Nucleic acid molecules encoding mammalian T cell growth factor P40 | 12/24/2013 | ||||
5,208,218 | Mammalian T cell growth factor P40 protein | 5/4/2010 | ||||
5,180,678 | Methods of detecting IL-9 | 9/19/2010 | ||||
Ethyol | 5,424,471 | Process for preparing crystalline forms | 7/13/2012 | |||
5,591,731 | Dosage forms of crystalline amifostine | 7/31/2012 | ||||
5,824,664 | Agents and methods for inhibiting HIV viral and protein expression using compounds that belong to a family which contains amifostine | 10/20/2015 | ||||
5,846,958 | Methods of stimulating hematopoietic progenitor cells using a compound that belong to a family which contains amifostine | 12/8/2015 | ||||
5,906,984 | Methods of stimulating hematopoietic progenitor cells using specific compounds, which include amifostine | 2/17/2015 | ||||
5,994,409 | Methods of treating toxicities associated with chemotherapy, a method of treating a nephrodisorder, and a method of treating xerostomia, all of which use a compound that belongs to a family which contains amifostine | 12/9/2017 | ||||
6,051,563 | Subcutaneous administration, method of protecting against toxicities associated with ionizing radiation | 2/12/2017 | ||||
6,127,351 | Methods of treating or protecting against toxicities associated with chemotherapy using a specific dosing regime, a method of stimulating bone marrow growth, and a method of treating myelodysplastic syndrome, all of which use a compound that belongs to a family which contains amifostine | 2/12/2017 | ||||
6,218,377 | Methods of treating or protecting against toxicities associated with specific chemotherapy agents, and a method of protecting normal tissue in cancer patients, both of which use a compound that belongs to a family which contains amifostine | 2/12/2017 | ||||
6,239,119 | Methods of treating damaged or infected mucosal tissue using a compounds that belongs to a family which contains amifostine | 4/26/2019 | ||||
6,384,259 | Stable Amorphous Amifostine Composition and Methods for the Preparation and Use of the Same | 11/16/2018 | ||||
6,407,278 | Stable Amorphous Amifostine Composition and Methods for the Preparation and Use of the Same | 11/16/2018 | ||||
6,489,312 | Novel Pharmaceutical Formulations Comprising Aminoalkyl Phosphorothioates | 6/15/2019 | ||||
NeuTrexin | 5,716,960 | Cystalline glucuronate hydrate salt | 2/10/2015 | |||
6,017,921 | Crystalline glucuronate salt | 1/13/2015 | ||||
6,017,922 | Thermally stable crystalline non-salts | 5/18/2018 | ||||
6,258,821 | Trimetrexate ascorbate and compositions comprising trimetrexate and ascorbic acid | 4/26/2019 | ||||
6,258,952 | Methods of producing monohydrate | 5/18/2018 | ||||
4,376,858 | 2,4-Diamino-5-methyl-6-[(3,4,5- trimethoxyanilino)methyl]quinazoline salts | 10/31/2004 | ||||
4,694,007 | Use of Trimetrexate as Antiparasitic Agent | 9/15/2006 | ||||
4,677,219 | Substituted Benzonitriles | 7/17/2006 |
5,160,727 | Tumor Cell Sensitization Method | 3/21/2010 | ||||
PALA | 5,491,135 | Methods of treating a viral infections (e.g., hepatitis B and C and secondary to HIV 1) | 2/13/2013 | |||
Platinum | 4,895,935 | Platinum Pharmaceuticals | 1/23/2007 | |||
CMV | 6,291,236 | Human CMV sequences and attenuated viruses | 3/31/2015 | |||
5,925,751 | Human CMV sequences and attenuated viruses | 3/31/2015 | ||||
5,721,354 | Human CMV sequences and attenuated viruses | 3/31/2015 | ||||
6,040,170 | Human CMV sequences and attenuated viruses | 3/31/2015 | ||||
EBV | 4,707,358 | Epstein-Barr virus gp350 subunit protein vaccine | 11/17/2004 | |||
6,054,130 | Non-splicing variants of EBV gp350 protein and gene | 4/18/2014 | ||||
5,824,508 | Non-splicing variants of EBV gp350 protein and gene | 4/18/2014 | ||||
6,458,364 | Non-Splicing Variants of GP350/220 | 04/24/2020 | ||||
Influenza | 5,690,937 | Temperature sensitive mutants of influenza | 6/5/2015 | |||
6,090,391 | Recombinant tryptophan mutants of influenza PB2 gene | 2/23/2016 | ||||
6,322,967 | Recombinant tryptophan mutants of influenza PB2 gene | 2/23/2016 | ||||
HSV | 4,554,159 | Vaccine against HSV-1 and HSV-2 | 11/19/2002 | |||
4,769,331 | Recombinant herpes simplex cloning methods and materials | 9/6/2005 | ||||
4,859,587 | Recombinant herpes simplex vectors and vaccines | 8/22/2006 | ||||
5,288,641 | Herpes simplex as a vector | 2/22/2011 | ||||
5,328,688 | Recombinant herpes simplex with 34.5 gene knockout | 6/12/2011 | ||||
5,599,691 | Herpes simplex as a vector | 2/4/2014 | ||||
5,641,651 | Synthetic HSV promoters and uses | 6/24/2014 | ||||
5,714,153 | Recombinant herpes simplex vaccines and vectors | 12/23/2012 | ||||
5,846,707 | Herpes simplex as a vector | 6/4/2004 | ||||
5,922,328 | Gamma 34.5 mutants of herpes simplex viruses | 9/11/2016 | ||||
6,071,692 | Herpes simplex as a gene expression vector and vaccine | 6/4/2004 | ||||
6,120,773 | Gamma 34.5 gene modification of herpes simplex viruses | 9/19/2017 | ||||
6,172,047 | Herpes viruses modified for use as cancer treatment | 1/9/2018 | ||||
Negative Stranded RNA Viruses | 5,166,057 | Recombinant negative strand RNA viruses | 11/24/2009 | |||
5,578,473 | Recombinant negative strand RNA viruses | 11/24/2009 | ||||
5,786,199 | Recombinant negative strand RNA viruses and vaccines | 7/28/2015 | ||||
5,820,871 | Recombinant negative strand RNA viruses — bicistronic | 10/13/2015 | ||||
5,854,037 | Recombinant negative strand RNA viruses | 12/29/2015 | ||||
6,001,634 | Recombinant negative strand RNA viruses | 8/28/2009 | ||||
6,022,726 | Attenuated negative strand RNA viruses and methods | 2/8/2017 | ||||
6,316,243 | Recombinant attenuated double strand RNA viruses | 11/13/2018 | ||||
5,840,520 | Recombinant RSV viruses | 11/24/2015 | ||||
VZV | 6,087,170 | VZV gene and mutant VZV viruses | 4/28/2014 |
- *
- The Company encourages any interested investor to obtain an independent legal analysis of the precise scope of the claims of the patents listed above.
U.S. Patents Owned or Licensed by MedImmune, Inc.